Trastuzumab

Form: IV & SQ Injection

Strength: IV : 150 mg/ 7.5 mL (vial); SQ: 600 mg/ 5 mL (syringe)

Reference Brands: Herceptin® (EU & US); Herceptin Hylecta® (subcutaneous formulation)

Category: Oncology Cancer Care

Trastuzumab is a monoclonal antibody used in oncology, primarily for the treatment of HER2-positive breast cancer and gastric cancer. It works by targeting the HER2 receptor, a protein that is overexpressed in some cancer cells, blocking its signaling and inhibiting cancer cell growth. Available as Herceptin® in both the US and EU, Trastuzumab is offered in intravenous (IV) and subcutaneous (SC) formulations. The IV formulation is commonly administered in 150 mg vials, while the SC formulation is available in 600 mg syringes. Used as part of combination therapy, it improves patient outcomes in HER2-positive cancers.